Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SCRT, Camrelizumab, Fluzoparib, and CAPEOX for LARC
NCT06516445Phase 2Recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, fluzoparib in rectal cancer, sponsored by Huazhong University of Science and Technology. Started Jun 2023; status: recruiting.
02
Drugs
camrelizumabfluzoparib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT06516445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06516445.